Ocugen Inc

OCGN remains in a Stage 2 advancing corrective reset with the active Bullish Pivot Point confirming structural repair. The recent volume-led breakout above resistance is positive, but price is extended above the rising 9/21 EMA zone and near overhead supply. Medium-term bias stays bullish in line with Stage 2, while short-term timing is unfavorable. We defer execution and stalk for a pullback into the supported EMA zone for cleaner entry. Primary risks include failure to hold the 9/21 EMA support and a reversal at the overhead resistance band.

• ↑OCU400 BLA rolling submission starts Q3 2026 for 2027 commercialization
• ↑OCU400 targets up to 98% of retinitis pigmentosa patients addressing broad mutations
• ↓Operating loss $19.4M and $0.06 net loss per share in Q1 2026